HB0052 not checked

Huahai Pharmaceutical (Huaota)

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
None yet
 
Trials
1 active
1 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“An antibody- drug conjugate (ADC) that targets CD73 with SN38 as the payload”In the company’s words, NCT06992687 on ClinicalTrials.gov
Tested for
Solid Tumors
Main trialPhase 1/2
“To evaluate the safety and tolerability of HB0052 in patients with advanced solid tumors”In the company’s words, NCT06992687 on ClinicalTrials.gov

Other drugs for Solid Tumors

All 2440 drugs for Solid Tumors

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1/2Enrolling by invitation 30 Sep 2025 A Study to Evaluate the Safety and Efficacy of HB0052 in Patients With Advanced Solid Tumors
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow HB0052

Following is part of Solo: you see every change to HB0052 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in